China Commercial Credit (CCCR) Reaches $2.68 After 8.00% Up Move; Stemline Therapeutics (STML) SI Decreased By 0.14%

August 1, 2017 - By Winifred Garcia

Stemline Therapeutics Incorporated (NASDAQ:STML) had a decrease of 0.14% in short interest. STML’s SI was 1.87 million shares in August as released by FINRA. Its down 0.14% from 1.87 million shares previously. With 198,800 avg volume, 9 days are for Stemline Therapeutics Incorporated (NASDAQ:STML)’s short sellers to cover STML’s short positions. The SI to Stemline Therapeutics Incorporated’s float is 11.69%. The stock decreased 0.54% or $0.05 during the last trading session, reaching $9.15. About 138,317 shares traded. Stemline Therapeutics Inc (NASDAQ:STML) has risen 52.65% since August 1, 2016 and is uptrending. It has outperformed by 35.95% the S&P500.

The stock of China Commercial Credit Inc (NASDAQ:CCCR) is a huge mover today! The stock increased 6.77% or $0.17 on August 1, reaching $2.68. About 52,906 shares traded. China Commercial Credit Inc (NASDAQ:CCCR) has risen 708.57% since August 1, 2016 and is uptrending. It has outperformed by 691.87% the S&P500.The move comes after 9 months positive chart setup for the $46.43 million company. It was reported on Aug, 1 by Barchart.com. We have $2.89 PT which if reached, will make NASDAQ:CCCR worth $3.71 million more.

Investors sentiment decreased to 0 in 2016 Q4. Its down 3.00, from 3 in 2016Q3. It worsened, as 2 investors sold China Commercial Credit Inc shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 97,569 shares or 49.69% less from 193,918 shares in 2016Q3 were reported. Blackrock Institutional Trust Company Na accumulated 9,469 shares. Renaissance has 88,100 shares for 0% of their portfolio.

Since May 1, 2017, it had 0 insider buys, and 1 sale for $72,000 activity. The insider Yi Long sold 30,000 shares worth $72,000.

China Commercial Credit, Inc. is engaged in offering financial services in China. The company has market cap of $46.43 million. The Company’s activities consist of providing direct loans, loan guarantees and financial leasing services to small-to-medium sized businesses , farmers and individuals in the city of Wujiang, Jiangsu Province. It currently has negative earnings. The Company’s loan and loan guarantee business is conducted through Wujiang Luxiang Rural Microcredit Co., Ltd.

Investors sentiment decreased to 1.9 in Q4 2016. Its down 0.05, from 1.95 in 2016Q3. It worsened, as 7 investors sold Stemline Therapeutics Inc shares while 14 reduced holdings. 14 funds opened positions while 26 raised stakes. 9.13 million shares or 9.47% more from 8.34 million shares in 2016Q3 were reported. Moreover, Millennium Mgmt Ltd Llc has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 164,302 shares. Blackrock Inc reported 0% in Stemline Therapeutics Inc (NASDAQ:STML). Jpmorgan Chase & has 25,121 shares for 0% of their portfolio. Morgan Stanley stated it has 0% in Stemline Therapeutics Inc (NASDAQ:STML). Northern Corp invested in 203,831 shares or 0% of the stock. Tower Research Ltd Liability (Trc) has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 457 shares. California State Teachers Retirement has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML). Intl Gru Inc invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Nationwide Fund Advisors reported 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). State Bank Of Montreal Can accumulated 0% or 6,836 shares. Ameriprise Incorporated holds 40,400 shares. Tiaa Cref Inv Mngmt Limited Com accumulated 54,311 shares. Blackrock Institutional Tru Na holds 276,656 shares. D E Shaw Inc stated it has 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). The Ohio-based Meeder Asset Mngmt Incorporated has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML).

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 7 analyst reports since November 10, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Friday, June 23 with “Buy”. The stock of Stemline Therapeutics Inc (NASDAQ:STML) earned “Outperform” rating by Wedbush on Monday, February 6. Cowen & Co maintained the shares of STML in report on Wednesday, June 14 with “Buy” rating. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 26.

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company has market cap of $229.81 million. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. It currently has negative earnings. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), present on a range of hematologic cancers.